Oppenheimer set a $28.00 price target on Syros Pharmaceuticals (NASDAQ:SYRS) in a report released on Monday. The firm currently has a buy rating on the stock. Oppenheimer also issued estimates for Syros Pharmaceuticals’ Q1 2018 earnings at ($0.59) EPS, Q2 2018 earnings at ($0.72) EPS, Q3 2018 earnings at ($0.74) EPS, Q4 2018 earnings at ($0.77) EPS, FY2018 earnings at ($2.83) EPS, FY2019 earnings at ($2.12) EPS, FY2020 earnings at ($0.19) EPS and FY2021 earnings at $1.70 EPS.

Other research analysts have also recently issued research reports about the company. Cowen restated a buy rating on shares of Syros Pharmaceuticals in a research note on Monday, December 11th. Zacks Investment Research upgraded Syros Pharmaceuticals from a hold rating to a buy rating and set a $11.00 price objective on the stock in a research note on Friday, January 5th. HC Wainwright restated a hold rating and set a $10.00 price objective on shares of Syros Pharmaceuticals in a research note on Thursday, December 21st. Roth Capital assumed coverage on Syros Pharmaceuticals in a research note on Monday, October 23rd. They set a neutral rating and a $15.00 price objective on the stock. Finally, JMP Securities upgraded Syros Pharmaceuticals from a market perform rating to an outperform rating and set a $33.00 price target on the stock in a research note on Thursday, September 28th. One analyst has rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating to the company’s stock. Syros Pharmaceuticals currently has a consensus rating of Buy and a consensus price target of $22.23.

Shares of Syros Pharmaceuticals (SYRS) traded down $0.08 on Monday, hitting $10.65. The company’s stock had a trading volume of 270,500 shares, compared to its average volume of 252,275. The firm has a market capitalization of $280.06 and a PE ratio of -6.12. Syros Pharmaceuticals has a 12 month low of $6.30 and a 12 month high of $24.38.

Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings data on Wednesday, November 8th. The company reported ($0.53) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.53). equities research analysts expect that Syros Pharmaceuticals will post -2.12 EPS for the current fiscal year.

In other Syros Pharmaceuticals news, Director Srinivas Akkaraju purchased 109,774 shares of the business’s stock in a transaction that occurred on Thursday, December 14th. The shares were acquired at an average price of $9.03 per share, for a total transaction of $991,259.22. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Jeremy P. Springhorn purchased 15,000 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The stock was acquired at an average price of $9.08 per share, for a total transaction of $136,200.00. The disclosure for this purchase can be found here. Insiders own 33.60% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the stock. Nationwide Fund Advisors lifted its stake in shares of Syros Pharmaceuticals by 249.8% in the second quarter. Nationwide Fund Advisors now owns 7,024 shares of the company’s stock worth $113,000 after acquiring an additional 5,016 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Syros Pharmaceuticals by 17.7% in the third quarter. Bank of New York Mellon Corp now owns 35,329 shares of the company’s stock worth $520,000 after acquiring an additional 5,305 shares in the last quarter. New York State Common Retirement Fund lifted its stake in shares of Syros Pharmaceuticals by 167.9% in the second quarter. New York State Common Retirement Fund now owns 13,400 shares of the company’s stock worth $216,000 after acquiring an additional 8,399 shares in the last quarter. Russell Investments Group Ltd. acquired a new position in shares of Syros Pharmaceuticals in the third quarter worth about $133,000. Finally, Ark Investment Management LLC lifted its stake in shares of Syros Pharmaceuticals by 114.7% in the second quarter. Ark Investment Management LLC now owns 17,705 shares of the company’s stock worth $285,000 after acquiring an additional 9,460 shares in the last quarter. Institutional investors and hedge funds own 57.96% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was first posted by Watch List News and is the property of of Watch List News. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://www.watchlistnews.com/oppenheimer-analysts-give-syros-pharmaceuticals-syrs-a-28-00-price-target/1804598.html.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.

Analyst Recommendations for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.